Management of malignant teratoma: does referral to a specialist unit matter?

@article{Harding1993ManagementOM,
  title={Management of malignant teratoma: does referral to a specialist unit matter?},
  author={M. J. Harding and James Paul and Stanley B. Kaye and Charles R. Gillis},
  journal={The Lancet},
  year={1993},
  volume={341},
  pages={999-1002}
}
The causes of geographical differences in cancer survival among regions of the UK are unclear. Population-based audit of management of patients with non-seminomatous germ-cell tumours (NSGCT) in the west of Scotland enabled us to assess the relative contributions to outcome of recognised prognostic factors, treatment centre, and protocol treatment. Data on treatment and outcome were analysed for 440 (97%) of 454 men with NSGCT diagnosed between 1975 and 1989. All but 11 patients were treated at… Expand
Management of ovarian cancer: referral to a multidisciplinary team matters.
TLDR
The results of this study support the contents of the 1991 Department of Health report on present acceptable practice in the management of ovarian cancer, circulated to gynaecologists and surgeons in Scotland in 1992. Expand
A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists.
TLDR
A detailed casenote review was performed on 55 patients registered with testicular non-seminomatous germ cell tumours between 1983 and 1988 under the Scottish Cancer Registration Scheme and who had died by 1992, showing significant differences between centres. Expand
Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration
TLDR
This report is a complete review of NSGCT patients treated in the authors' minor university clinic and survival rates are comparable to recently published data, due to a commitment to multicentre protocol and research collaboration. Expand
Who should manage germ cell tumours of the testis?
  • Mead
  • Medicine
  • BJU international
  • 1999
TLDR
This issue of BJU International contains two papers with conflicting messages, one on the management of testicular cancer and the other on morbidity and the financial and psychological cost of achieving cure. Expand
A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists.
TLDR
Considerable variation in the management of testicular NSGCT in Scotland has been identified and the introduction of management guidelines should result in a more consistent approach to the care of these patients. Expand
Changes in the incidence and mortality of testicular cancer in Scotland with particular reference to the outcome of older patients treated for non-seminomatous germ cell tumours.
TLDR
Univariate and multivariate analysis of the data obtained on 440 patients with NSGCT showed age was not a prognostic factor influencing survival, and older patients should be approached with the same curative intent as for younger patients and the same expectation of success. Expand
Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
TLDR
The treatment outcome of a single institution in Japan is not different from that of the institutions participating in the International Germ Cell Cancer Consensus Group (IGCCCG) and the Indiana University classification. Expand
Testicular Cancer
TLDR
The treatment of germ-cell tumours of the testis can be considered as a model for cancer management, representing public education, diagnosis and cure with long term follow-up, and more time can be spent reducing acute and late toxicity in long term survivors and studying sociopsychological aspects in these men. Expand
Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience.
TLDR
After 612 patient-years of observation no case of secondary leukaemia was observed among 119 surviving patients who had received etoposide as part of their treatment, indicating some evidence that cumulative experience translates into improved survival and cure rates for patients with poor-risk metastatic disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985.
TLDR
It is confirmed that the majority of patients now presenting with metastatic NSGCT are curable with chemotherapy, but that a small proportion with very large volume metastases or extragonadal tumours require alternative chemotherapy schedules. Expand
Rare cancers and specialist centres.
TLDR
For patients with early disease the dispute over the relative merits of radiotherapy and surgery to the retroperitoneal lymph nodes has become outdated by advances in staging procedures and the dramatic effects of cytotoxic chemotherapy. Expand
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party.
  • G. Mead, S. Stenning, +6 authors P. Cook
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
Assessment of prognostic factors in a large population of patients with metastatic nonseminomatous germ cell tumors arising in gonadal or extragonadal sites found a good-prognosis group having none of these features had a 3-year survival rate of 93%. Expand
Changes in testicular cancer in Scotland.
TLDR
The ever-widening gap between the increasing incidence rate and the declining mortality rate, particularly apparent in the high-risk age group 15-44, indicates an improving prognosis for patients with this malignancy in Scotland. Expand
Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.
  • N. Aass, O. Klepp, +6 authors S. Fosså
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1991
TLDR
Between 1981 and 1986, 200 consecutive patients with metastatic nonseminomatous testicular cancer were entered into the Swedish Norwegian Testicular Cancer project from 14 hospitals, and the overall 5-year survival rate was 82%. Expand
Centralisation of treatment and survival rates for cancer.
  • C. Stiller
  • Medicine
  • Archives of disease in childhood
  • 1988
TLDR
Children with acute non-lymphoblastic leukaemia, non-Hodgkin's lymphoma, Ewing's tumour, rhabdomyosarcoma, and (during 1981-84) osteosarComa treated at paediatric oncology centres had significantly higher survival rates than those treated elsewhere. Expand
HISTOPATHOLOGY IN THE PREDICTION OF RELAPSE OF PATIENTS WITH STAGE I TESTICULAR TERATOMA TREATED BY ORCHIDECTOMY ALONE
TLDR
259 patients with stage I non-seminomatous germ-cell testicular teratoma treated by orchidectomy alone and monitored at one often centres in the United Kingdom were followed for a median of 30 months, with a 2-year relapse-free rate of 74%, falling to 68% at 4 years. Expand
Current optimum management of anaplastic germ cell tumours of the testis and other sites.
TLDR
It is believed that POMB/ACE chemotherapy, followed by surgery in selected cases, is currently the best treatment for patients with AGCT. Expand
Physician-dependent prognostic variables in the management of testicular cancer.
A study of 246 cases of germ cell testicular cancer in Ireland between 1980 and 1985 confirmed that the personnel and the manner of management can significantly influence the outcome. InadequateExpand
Influence of delay in diagnosis on prognosis in testicular teratoma.
TLDR
Analysis of relapse-free survival excluding stage I marker-negative patients gave results similar to those reported by the MRC Working Party on Testicular Tumours (1985). Expand
...
1
2
3
...